- Conditions
- Colorectal Cancer Metastatic
- Interventions
- TheraSphere
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 30 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Endometrial Endometrioid Adenocarcinoma
- Interventions
- Abemaciclib, Letrozole, Therapeutic Conventional Surgery
- Drug · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Prostatic Neoplasms
- Interventions
- Monoclonal Antibody J591, Recombinant Interleukin-2
- Drug
- Lead sponsor
- BZL Biologics
- Industry
- Eligibility
- 21 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, Carboplatin, Cisplatin, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Relatlimab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 83
- States / cities
- Dublin, California • Fremont, California • Fresno, California + 62 more
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Interventions
- lenalidomide, cyclophosphamide, laboratory biomarker analysis, questionnaire administration, quality-of-life assessment
- Drug · Other
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Lung Cancer
- Interventions
- carboplatin, etoposide, exisulind
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 81
- States / cities
- Anniston, Alabama • La Jolla, California • Los Angeles, California + 57 more
- Conditions
- Triple Negative Breast Cancer
- Interventions
- No drug
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 760 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Basking Ridge, New Jersey
- Conditions
- Ewing's Sarcoma, Rhabdomyosarcoma
- Interventions
- therapeutic autologous dendritic cells, indinavir sulfate, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 5 Years to 35 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, Melanoma, Non-small Cell Lung Cancer
- Interventions
- Synthetic long peptide personalized cancer vaccine, Poly ICLC, Signatera or Altera testing
- Biological · Drug · Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 3
- States / cities
- Orlando, Florida • St Louis, Missouri • Columbus, Ohio
- Conditions
- Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC), Extensive-stage Small Cell Lung Cancer (SCLC), Recurrent Small Cell Lung Cancer (SCLC), Tumors Metastatic to Brain, Metastatic Breast Cancer (mBC)
- Interventions
- Pegylated Irinotecan
- Drug
- Lead sponsor
- Joel Neal
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Myeloproliferative Diseases
- Interventions
- Pacritinib, Busulfan, Questionnaires, Phone Calls, Allogeneic Stem Cell Transplantation, Fludarabine
- Drug · Behavioral · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ovarian Cancer
- Interventions
- Follicle Stimulating Hormone Receptor T Cells
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Solid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma)
- Interventions
- Itacitinib, erlotinib, placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Ogden, Utah
- Conditions
- Squamous Cell Carcinoma of Oropharynx
- Interventions
- IMRT, Cisplatin, Carboplatin
- Radiation · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Metastatic Renal Cell Carcinoma Treated With Cabozantinib
- Interventions
- Usability of an electronic symptom management application
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Raleigh, North Carolina
- Conditions
- Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma, Locally Advanced Breast Cancer, Metastatic Breast Cancer, Inflammatory Breast Cancer, Triple Negative Breast Cancer (TNBC), Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma
- Interventions
- Onvansertib, Paclitaxel
- Drug
- Lead sponsor
- Antonio Giordano, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- irofulven
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- vinorelbine tartrate
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Interventions
- TU2218 + KEYTRUDA® (Pembrolizumab)
- Drug
- Lead sponsor
- TiumBio Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 3
- States / cities
- San Antonio, Texas • Tyler, Texas • Spokane, Washington
- Conditions
- Prostate Cancer
- Interventions
- Placebo, Methylphenidate, Counseling Sessions, Sham Exercise, Standardized Exercise Intervention Program, Cognitive Behavioral Therapy (CBT)
- Other · Drug · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Dermatologic Complications, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- sunscreen, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 208
- States / cities
- Jacksonville, Florida • Aurora, Illinois • Bloomington, Illinois + 130 more
- Conditions
- Cholangiocarcinoma
- Interventions
- RRx-001, Gemcitabine and cisplatin
- Drug
- Lead sponsor
- EpicentRx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Estrogen Receptor Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Positron Emission Tomography
- Procedure · Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Breast Cancer
- Interventions
- Radiomics on MRI, microbubble CEUS Contrast Enhanced Ultrasound (CEUS)
- Radiation · Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas